专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2021188883A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASE USING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) 审中-公开
公开(公告)号：WO2021188883A1
公开(公告)日：2021-09-23
申请号：PCT/US2021/023134
申请日：2021-03-19
申请人： THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE , POTTER, Huntington , BOYD, Timothy , CLARKE, Penny , TYLER, Kenneth L. , KENDALL, Lon , STONEDAHL, Sarah
发明人： POTTER, Huntington , BOYD, Timothy , CLARKE, Penny , TYLER, Kenneth L. , KENDALL, Lon , STONEDAHL, Sarah
IPC分类号： A61K38/38 , A61P7/00 , C07H21/04
摘要： Embodiments herein relate to novel compositions and methods for treating viral infections and viral infection-related conditions. In some embodiments, compositions include, but are not limited to, at least one pro-inflammatory cytokine. In accordance with these embodiments, a proinflammatory cytokine can include Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) alone or in combination with other agents administered separately or together. In some embodiments, compositions including GM-CSF can be administered to a subject exposed to, suspected of having been exposed to, or having a viral infection. In other embodiments, the compositions treat, ameliorate or prevent a complication related to viral infection including, but not limited to, a central nervous system infection or condition and a lung infection or condition.

2. 发明申请

WO1997007213A2 ASSAY FOR IDENTIFYING GENES CAUSING CHROMOSOME NON-DISJUNCTION 审中-公开
标题翻译：用于识别基因导致染色体不分离的测定
公开(公告)号：WO1997007213A2
公开(公告)日：1997-02-27
申请号：PCT/US1996013314
申请日：1996-08-15
申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE , POTTER, Huntington , LI, Jinhe
发明人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE
IPC分类号： C12N15/12
CPC分类号： G01N33/5011 , A61K38/00 , C07K14/4711 , C12N15/10 , C12Q1/68 , C12Q1/6897 , G01N33/5008 , G01N33/502
摘要： Disclosed is a method of identifying genes whose gene products cause chromosome missegregation. The method involves transfecting a mammalian gene being assessed into a cell and then assessing whether the progeny cells have increased aneuploidy or increased chromosome breaks or translocations compared with cells that have not been transfected with the gene. Genes identified in this manner are likely to be involved in causing diseases such as cancer and Alzheimer's Disease, which result from improper chromosome segregation. Also disclosed is a method of identifying agents which can be used in the treatment of diseases caused by improper chromosome segregation. The method involves treating cells that have been transfected with a gene whose gene product causes improper chromosome segregation with an agent being assessed. Cells showing less aneuploidy or less chromosomal breakage or translocation compared with untreated cells indicate that the agent is useful in the treatment of diseases caused by improper chromosome segregation.
摘要翻译：公开了一种识别基因产物导致染色体错误分离的基因的方法。该方法涉及将待评估的哺乳动物基因转染到细胞中，然后评估与未用该基因转染的细胞相比，后代细胞是否增加非整倍体或增加的染色体断裂或易位。以这种方式鉴定的基因可能参与由于不适当的染色体分离而引起的癌症和阿尔茨海默病等疾病。还公开了一种鉴定可用于治疗由不适当的染色体分离引起的疾病的药剂的方法。该方法涉及用被评估的试剂处理基因产物导致不适当的染色体分离的基因转染的细胞。与未经处理的细胞相比，显示较少非整倍体或较少染色体断裂或易位的细胞表明该试剂可用于治疗由不适当的染色体分离引起的疾病。

3. 发明申请

WO1996035126A1 ASSESSING CALCINEURIN'S ROLE IN IMMUNOSUPPRESSION AND NEUROTOXICITY 审中-公开
标题翻译：评估CALCINEURIN在免疫抑制和神经毒性方面的作用
公开(公告)号：WO1996035126A1
公开(公告)日：1996-11-07
申请号：PCT/US1996006152
申请日：1996-05-02
申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE , ZHANG, Wei , SEIDMAN, Jonathan, G. , KAYYALI, Usamah, S. , POTTER, Huntington
发明人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE
IPC分类号： G01N33/68
CPC分类号： C12N15/8509 , A01K67/0276 , A01K2207/15 , A01K2217/00 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0312 , G01N33/6896
摘要： The present invention relates to a method of identifying drugs or agents which have immunosuppressive effects through or as a result of their effect on calcineurin, including drugs which affect the calcineurin A alpha (CNA alpha ) subunit or the calcineurin A beta (CNA beta ) subunit. In addition, the present invention relates to a method of identifying drugs which reduce (partially or totally) phosphorylation of the microtubule-associated protein tau, in the nervous system of a mammal; a method of identifying drugs which reduce (partially or totally) paired helical filament formation in the nervous system of a mammal; and a method of identifying drugs which reduce (partially or totally) formation of paired helical filaments, amyloid deposits or both. The present invention also relates to transgenic non-human mammals, such as rodents and particularly mice, which lack a functional calcineurin gene and, thus, have disrupted calcineurin expression.
摘要翻译：本发明涉及通过或影响钙调神经磷酸酶（包括影响钙调神经磷酸酶Aα（CNAα））亚基或钙调神经磷酸酶Aβ（CNAβ）亚基的药物，或通过其对钙调神经磷酸酶的影响来鉴定具有免疫抑制作用的药物或药剂的方法。。此外，本发明涉及鉴定在哺乳动物的神经系统中减少（部分或全部）微管相关蛋白tau的磷酸化的药物的方法。一种鉴定在哺乳动物的神经系统中减少（部分或完全）配对的螺旋丝状细胞形成的药物的方法; 以及鉴定减少（部分或全部）成对的螺旋丝，淀粉样蛋白沉积物或两者的药物的方法。本发明还涉及缺乏功能性钙调神经磷酸酶基因并因此破坏钙调神经磷酸酶表达的转基因非人哺乳动物，例如啮齿动物，特别是小鼠。

4. 发明申请

WO2006036637A3 ASSAY METHOD FOR DRUGS TO TREAT ATHEROSCLEROSIS, CANCER AND ALZHEIMER'S DISEASE 审中-公开
标题翻译：检测药物治疗动脉粥样硬化，癌症和阿尔茨海默病的方法
公开(公告)号：WO2006036637A3
公开(公告)日：2006-06-22
申请号：PCT/US2005033522
申请日：2005-09-19
申请人： UNIV SOUTH FLORIDA , POTTER HUNTINGTON
发明人： POTTER HUNTINGTON
IPC分类号： C12Q1/60
CPC分类号： G01N33/5008 , G01N33/502 , G01N33/5088 , G01N33/92 , G01N2333/9125
摘要： An assay t screen for potentially benefical drugs against atherosclerosis, cancer and Alzheimeer's disease, and their effectiveness in vitro. The assay is comprised of a system where LDL or cholesterol is given to various cells together with the drug being tested and then chromosome segregation and aneuploidy are detected using probes specific for targeted chromosomes. A related assay tests the ability of the drugs alter the fluidity of membranes.
摘要翻译：用于潜在有益药物抗动脉粥样硬化，癌症和阿尔茨海默氏病的化验t筛选及其在体外的有效性。该测定法包括将LDL或胆固醇与待测药物一起给予各种细胞的系统，然后使用针对目标染色体的特异性探针检测染色体分离和非整倍性。一项相关的分析测试药物改变膜流动性的能力。

5. 发明申请

WO2006036637A2 ASSAY METHOD FOR DRUGS TO TREAT ATHEROSCLEROSIS, CANCER AND ALZHEIMER’S DISEASE 审中-公开
标题翻译：药物治疗甲状腺功能亢进症，癌症和阿尔茨海默病的测定方法
公开(公告)号：WO2006036637A2
公开(公告)日：2006-04-06
申请号：PCT/US2005/033522
申请日：2005-09-19
申请人： UNIVERSITY OF SOUTH FLORIDA , POTTER, Huntington
发明人： POTTER, Huntington
IPC分类号： G01N33/574
CPC分类号： G01N33/5008 , G01N33/502 , G01N33/5088 , G01N33/92 , G01N2333/9125
摘要： An assay t screen for potentially benefical drugs against atherosclerosis, cancer and Alzheimeer’s disease, and their effectiveness in vitro. The assay is comprised of a system where LDL or cholesterol is given to various cells together with the drug being tested and then chromosome segregation and aneuploidy are detected using probes specific for targeted chromosomes. A related assay tests the ability of the drugs alter the fluidity of membranes.
摘要翻译：筛选针对动脉粥样硬化，癌症和阿尔茨海默病的潜在有益药物及其在体外的有效性的检测。该测定由其中将LDL或胆固醇与待测试的药物一起提供给各种细胞的系统组成，然后使用针对靶向染色体特异的探针检测染色体分离和非整倍体。相关测定测试药物改变膜流动性的能力。

6. 发明申请

WO2012177903A4 METHODS OF TREATING COGNITIVE IMPAIRMENT 审中-公开
标题翻译：治疗认知障碍的方法
公开(公告)号：WO2012177903A4
公开(公告)日：2013-06-06
申请号：PCT/US2012043581
申请日：2012-06-21
申请人： UNIV SOUTH FLORIDA , POTTER HUNTINGTON , ARENDASH GARY W , BENNETT STEVEN , BOYD TIMOTHY
发明人： POTTER HUNTINGTON , ARENDASH GARY W , BENNETT STEVEN , BOYD TIMOTHY
IPC分类号： A61K48/00 , A61K38/19 , A61K38/20 , A61P25/00 , A61P29/00
CPC分类号： A61K38/193 , A01K67/0275 , A01K2207/30 , A01K2217/052 , A01K2217/15 , A01K2227/105 , A01K2267/0312 , A01K2267/0356 , A61K38/1709 , A61K38/1816 , A61K48/005 , C07K14/535 , A61K2300/00
摘要： The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1 alpha), insulin like growth factor- 1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony- stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.
摘要翻译：本发明涉及用于治疗具有认知障碍的人或动物的材料和方法。在一个实施方案中，所述方法包括施用有效量的一种或多种炎症介质，例如，fms相关的酪氨酸激酶3（Flt3）配体，白细胞介素-6（IL-6），巨噬细胞迁移抑制因子（MIF）），白细胞介素-1（IL-1），白细胞介素-3（IL-3），红细胞生成素（EPO），血管内皮生长因子A（VEGF-A），缺氧诱导型转录因子（HIF-1α）生长因子-1（IGF-1），肿瘤坏死因子（TNF），粒细胞集落刺激因子（G-CSF），粒细胞/巨噬细胞集落刺激因子（GM-CSF），巨噬细胞集落刺激因子），干细胞因子（SCF），达比泊汀（ARANESP）和金属蛋白酶，需要治疗的动物或人。

7. 发明申请

WO2012177903A2 METHODS OF TREATING COGNITIVE IMPAIRMENT 审中-公开
标题翻译：治疗认知障碍的方法
公开(公告)号：WO2012177903A2
公开(公告)日：2012-12-27
申请号：PCT/US2012/043581
申请日：2012-06-21
申请人： UNIVERSITY OF SOUTH FLORIDA , POTTER, Huntington , ARENDASH, Gary, W. , BENNETT, Steven , BOYD, Timothy
发明人： POTTER, Huntington , ARENDASH, Gary, W. , BENNETT, Steven , BOYD, Timothy
IPC分类号： A61K48/00 , A61K38/19 , A61K38/20 , A61P25/00 , A61P29/00
CPC分类号： A61K38/193 , A01K67/0275 , A01K2207/30 , A01K2217/052 , A01K2217/15 , A01K2227/105 , A01K2267/0312 , A01K2267/0356 , A61K38/1709 , A61K38/1816 , A61K48/005 , C07K14/535 , A61K2300/00
摘要： The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1 alpha), insulin like growth factor- 1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony- stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.
摘要翻译：本发明涉及用于治疗具有认知障碍的人或动物的材料和方法。在一个实施方案中，所述方法包括施用有效量的一种或多种炎症介质，例如，fms相关的酪氨酸激酶3（Flt3）配体，白细胞介素-6（IL-6），巨噬细胞迁移抑制因子（MIF）），白细胞介素-1（IL-1），白细胞介素-3（IL-3），红细胞生成素（EPO），血管内皮生长因子A（VEGF-A），缺氧诱导型转录因子（HIF-1α）生长因子-1（IGF-1），肿瘤坏死因子（TNF），粒细胞集落刺激因子（G-CSF），粒细胞/巨噬细胞集落刺激因子（GM-CSF），巨噬细胞集落刺激因子），干细胞因子（SCF），达比泊汀（ARANESP）和金属蛋白酶，需要治疗的动物或人。

8. 发明申请

WO2010017224A2 METHODS OF TREATING COGNITIVE IMPAIRMENT 审中-公开
标题翻译：治疗认知障碍的方法
公开(公告)号：WO2010017224A2
公开(公告)日：2010-02-11
申请号：PCT/US2009052742
申请日：2009-08-04
申请人： UNIV SOUTH FLORIDA , POTTER HUNTINGTON , ARENDASH GARY W , BENNETT STEVEN , BOYD TIMOTHY
发明人： POTTER HUNTINGTON , ARENDASH GARY W , BENNETT STEVEN , BOYD TIMOTHY
IPC分类号： A61K38/19 , A61K38/18 , A61K38/20 , A61P25/28
CPC分类号： A61K38/193 , A61K38/1709 , A61K38/1816 , A61K2300/00
摘要： The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. Tn one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interlcukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-I), interleukin-3 (IL-3). erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor- 1 (1GF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony- stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and mctalloproteinases, to an animal or person in need of treatment.
摘要翻译：本发明涉及用于治疗患有认知障碍的人或动物的材料和方法。在一个实施方案中，所述方法包括施用有效量的一种或多种炎症介质，例如fms相关的酪氨酸激酶3（Flt3）配体，interlcukin-6（IL-6），巨噬细胞迁移抑制因子（MIF ），白细胞介素-1（IL-1），白细胞介素-3（IL-3）。红细胞生成素（EPO），血管内皮生长因子A（VEGF-A），缺氧诱导转录因子（HIF-1α），胰岛素样生长因子-1（1GF-1），肿瘤坏死因子（TNF），粒细胞集落刺激（G-CSF），粒细胞/巨噬细胞集落刺激因子（GM-CSF），巨噬细胞集落刺激因子（M-CSF），干细胞因子（SCF），达贝泊汀（ARANESP）需要治疗的人。

9. 发明申请

WO9612736A2 COMPOUNDS AND METHODS FOR INHIBITING beta -PROTEIN FILAMENT FORMATION AND NEUROTOXICITY 审中-公开
标题翻译：抑制β-PROTEIN FILAMENT形成和神经毒性的化合物和方法
公开(公告)号：WO9612736A2
公开(公告)日：1996-05-02
申请号：PCT/US9513681
申请日：1995-10-25
申请人： HARVARD COLLEGE , POTTER HUNTINGTON
发明人： POTTER HUNTINGTON
IPC分类号： A61K38/00 , C07K14/47 , C12Q1/37 , C12Q1/44 , G01N33/68 , A61K38/17 , C07K14/775
CPC分类号： C12Q1/37 , A61K38/00 , C07K14/4711 , C12Q1/44 , G01N33/6896 , G01N2333/4709 , G01N2333/8125 , G01N2500/20 , G01N2800/2821
摘要： Methods of treating an individual with Alzheimer's disease by administering to the patient a therapeutically effective dose of a compound which interferes with the interaction between Alzheimer beta -protein and Apolipoprotein E4 or alpha 1-antichymotrypsin, thereby suppressing the formation of Alzheimer beta -protein filaments and the neurotoxic effects of these filaments. The present invention also refers to methods of screening for compounds which are effective drugs for treating Alzheimer's disease. These methods comprise screening for compounds which suppress the formation of Alzheimer beta -protein filaments in the presence of promoting factors and which suppress the neurotoxic effects of these filaments formed in the presence of promoting factors.
摘要翻译：通过向患者施用治疗有效剂量的干扰阿尔茨海默氏病β-蛋白质和载脂蛋白E4或α1-抗胰凝乳蛋白酶之间的相互作用的化合物，从而抑制阿尔茨海默氏病β-蛋白细丝的形成，以及这些细丝的神经毒性作用。本发明还涉及筛选作为治疗阿尔茨海默病的有效药物的化合物的方法。这些方法包括筛选在促进因子存在下抑制阿尔茨海默氏病β-蛋白细丝形成的化合物，并且抑制在促进因子存在下形成的这些细丝的神经毒性作用。

10. 发明申请

WO2012177903A3 METHODS OF TREATING COGNITIVE IMPAIRMENT 审中-公开
标题翻译：治疗认知障碍的方法
公开(公告)号：WO2012177903A3
公开(公告)日：2013-04-04
申请号：PCT/US2012043581
申请日：2012-06-21
申请人： UNIV SOUTH FLORIDA , POTTER HUNTINGTON , ARENDASH GARY W , BENNETT STEVEN , BOYD TIMOTHY
发明人： POTTER HUNTINGTON , ARENDASH GARY W , BENNETT STEVEN , BOYD TIMOTHY
IPC分类号： A61K48/00 , A61K38/19 , A61K38/20 , A61P25/00 , A61P29/00
CPC分类号： A61K38/193 , A01K67/0275 , A01K2207/30 , A01K2217/052 , A01K2217/15 , A01K2227/105 , A01K2267/0312 , A01K2267/0356 , A61K38/1709 , A61K38/1816 , A61K48/005 , C07K14/535 , A61K2300/00
摘要： The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1 alpha), insulin like growth factor- 1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony- stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.
摘要翻译：本发明涉及用于治疗患有认知障碍的人或动物的材料和方法。在一个实施方案中，所述方法包括施用有效量的一种或多种炎症介质，例如fms相关酪氨酸激酶3（Flt3）配体，白细胞介素-6（IL-6），巨噬细胞迁移抑制因子（MIF ），白介素-1（IL-1），白细胞介素-3（IL-3），促红细胞生成素（EPO），血管内皮生长因子A（VEGF-A），缺氧诱导转录因子（HIF-1α），胰岛素样生长因子-1（IGF-1），肿瘤坏死因子（TNF），粒细胞集落刺激因子（G-CSF），粒细胞/巨噬细胞集落刺激因子（GM-CSF），巨噬细胞集落刺激因子），干细胞因子（SCF），达贝泊汀（ARANESP）和金属蛋白酶给需要治疗的动物或人。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式